Fig. 1

Flow chart for the selection of four INF (infliximab) groups. 96 INF-naïve biosimilar users and 2,149 INF-naïve bio-originator users were ≥ 18 years at index date, had consistent baseline medical and pharmacy coverage and without baseline use of INF bio-originator or biosimilar. 223 prevalent INF biosimilar users and 10,970 prevalent INF bio-originator users were ≥ 18 years at index date, had consistent baseline medical and pharmacy coverage, and had baseline use of INF bio-originator and no baseline use of INF biosimilar